Seattle, WA November 9, 2015--Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical diseases, will present new, positive dalazatide data at the American College of Rheumatology’s (ACR) Annual Meeting in San Francisco, from its recent Phase 1b active plaque psoriasis clinical trial as well as encouraging dalazatide research in lupus from its collaboration with Seattle Children’s Research Institute (SCRI), and in ANCA Vasculitis from its study with the University of Groningen in the Netherlands.
Dalazatide (formerly ShK-186) is a potent inhibitor of the Kv1.3 potassium channel, and a first-in-class drug candidate. It has demonstrated potential to selectively target autoimmune disease-causing cells while leaving intact the protective immune response.
Updated research from Kineta’s dalazatide proof of concept psoriasis trial presented at ACR shows validated blood biomarkers that confirm the drug’s mechanism of action for psoriasis. Kineta and its collaborators identified a unique set of cell population markers and cytokines from psoriasis patients that confirm both drug activity and clinical response to dalazatide treatment.
“These findings are exciting as they validate the novel mechanism of action of dalazatide, and the relevance of this new approach to managing autoimmune diseases,” said Shawn Iadonato, Chief Scientific Officer at Kineta. ”The consistent immune modulating activity we are finding from these studies across multiple disease indications is quite compelling and suggests a role for dalazatide in a number of autoimmune indications.”
Link to poster
Lupus research results
Kineta and SCRI will present new lupus research on November 10 at the conference which demonstrates that dalazatide can decrease a group of cytokines in ex vivo studies. Importantly these results show that dalazatide has the ability to suppress those cytokines which are associated with disease inflammation and damage to lupus patients to a degree similar to traditional but toxic immune therapies such as cyclosporine A.
“Our new data demonstrate that cells from pediatric and adult lupus patients are sensitive to dalazatide - the effector memory cells can be blocked very well, suggesting that this agent may be effective in treating lupus patients,” said Anne Stevens, a leading pediatrician and rheumatology researcher at Seattle Children’s Research Institute.
ANCA Vasculitis
Kineta and the University of Groningen also presented consistent data from a collaborative study to support dalzatide’s ability to normalize pro-inflammatory cytokines in the appropriate T-cell populations (CD4+ TEM cells) ex vivo. The study also showed that dalazatide does not have an effect on naïve and central memory T-cells, thus providing a very specific, targeted immune response. This data suggests that dalazatide may be of benefit in the treatment of ANCA vasculitis.
Link to ANCA poster
About dalazatide
Dalazatide (formerly ShK-186) is a novel therapy being developed by Kineta with potential to target an array of autoimmune diseases utilizing a new mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel - a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for autoimmune diseases including lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, asthma, atopic dermatitis and autoimmune eye diseases.
Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement of novel drug candidates derived from leading edge scientific research. Our world class scientists are pioneers in developing life-changing classes of new drugs designed to be more effective and safer than current medicines. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, www.Kinetabio.com
Help employers find you! Check out all the jobs and post your resume.
Dalazatide (formerly ShK-186) is a potent inhibitor of the Kv1.3 potassium channel, and a first-in-class drug candidate. It has demonstrated potential to selectively target autoimmune disease-causing cells while leaving intact the protective immune response.
Updated research from Kineta’s dalazatide proof of concept psoriasis trial presented at ACR shows validated blood biomarkers that confirm the drug’s mechanism of action for psoriasis. Kineta and its collaborators identified a unique set of cell population markers and cytokines from psoriasis patients that confirm both drug activity and clinical response to dalazatide treatment.
“These findings are exciting as they validate the novel mechanism of action of dalazatide, and the relevance of this new approach to managing autoimmune diseases,” said Shawn Iadonato, Chief Scientific Officer at Kineta. ”The consistent immune modulating activity we are finding from these studies across multiple disease indications is quite compelling and suggests a role for dalazatide in a number of autoimmune indications.”
Link to poster
Lupus research results
Kineta and SCRI will present new lupus research on November 10 at the conference which demonstrates that dalazatide can decrease a group of cytokines in ex vivo studies. Importantly these results show that dalazatide has the ability to suppress those cytokines which are associated with disease inflammation and damage to lupus patients to a degree similar to traditional but toxic immune therapies such as cyclosporine A.
“Our new data demonstrate that cells from pediatric and adult lupus patients are sensitive to dalazatide - the effector memory cells can be blocked very well, suggesting that this agent may be effective in treating lupus patients,” said Anne Stevens, a leading pediatrician and rheumatology researcher at Seattle Children’s Research Institute.
ANCA Vasculitis
Kineta and the University of Groningen also presented consistent data from a collaborative study to support dalzatide’s ability to normalize pro-inflammatory cytokines in the appropriate T-cell populations (CD4+ TEM cells) ex vivo. The study also showed that dalazatide does not have an effect on naïve and central memory T-cells, thus providing a very specific, targeted immune response. This data suggests that dalazatide may be of benefit in the treatment of ANCA vasculitis.
Link to ANCA poster
About dalazatide
Dalazatide (formerly ShK-186) is a novel therapy being developed by Kineta with potential to target an array of autoimmune diseases utilizing a new mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel - a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for autoimmune diseases including lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, asthma, atopic dermatitis and autoimmune eye diseases.
Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement of novel drug candidates derived from leading edge scientific research. Our world class scientists are pioneers in developing life-changing classes of new drugs designed to be more effective and safer than current medicines. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, www.Kinetabio.com
Help employers find you! Check out all the jobs and post your resume.
